These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30853551)

  • 1. Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons From the Population With Advanced Cancer.
    Bull J; Bonsignore L; Massie L; Riggs A; Knotkova H; Wellman C; Portenoy R
    J Pain Symptom Manage; 2019 May; 57(5):e5-e8. PubMed ID: 30853551
    [No Abstract]   [Full Text] [Related]  

  • 2. Naloxegol rescue with methylnaltrexone highly effective.
    Brocklebank J; Miller EJ; Fingas S
    BMJ Support Palliat Care; 2020 Sep; 10(3):316-317. PubMed ID: 32709705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxegol (Movantik) for opioid-induced constipation.
    Med Lett Drugs Ther; 2015 Sep; 57(1478):135-7. PubMed ID: 26393826
    [No Abstract]   [Full Text] [Related]  

  • 4. Medical Management of Opioid-Induced Constipation.
    Rao VL; Micic D; Davis AM
    JAMA; 2019 Dec; 322(22):2241-2242. PubMed ID: 31682706
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis.
    Cobo Dols M; Beato Zambrano C; Cabezón Gutiérrez L; Chicas Sett R; Blancas López-Barajas MI; García Navalón F; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Jiménez López AJ; Huerta González I; Sanz Yagüe A; Soler López B
    BMJ Support Palliat Care; 2021 Mar; 11(1):25-31. PubMed ID: 32376758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
    Webster L; Tummala R; Diva U; Lappalainen J
    J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ▼Naloxegol for opioid-induced constipation.
    Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxegol oxalate, pirfenidone, and nintedanib.
    Hussar DA; Jeon MM
    J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491
    [No Abstract]   [Full Text] [Related]  

  • 9. Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report.
    Gálvez R; Maire C; Tovar I; Vargas P
    A A Pract; 2018 Jul; 11(1):22-24. PubMed ID: 29634552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating naloxegol for the treatment of opioid-induced constipation.
    Daniali M; Nikfar S; Abdollahi M
    Expert Opin Pharmacother; 2020 Jun; 21(8):883-891. PubMed ID: 32129103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
    Jones R; Prommer E; Backstedt D
    Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid-Induced Constipation Part 2: Newer Therapies #295.
    Badke A; Rosielle DA
    J Palliat Med; 2015 Oct; 18(10):893-4. PubMed ID: 26439728
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxegol: a review of its use in patients with opioid-induced constipation.
    Garnock-Jones KP
    Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GI relief may come sooner than later for patients with chronic noncancer pain.
    Thompson CA
    Am J Health Syst Pharm; 2014 Jul; 71(14):1153-5. PubMed ID: 24973366
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study.
    Shimizu M; Maeda I; Kessoku T; Ishiki H; Matsuura T; Hiratsuka Y; Matsuda Y; Hasegawa T; Imai K; Oyamada S; Satomi E;
    Support Care Cancer; 2024 Jul; 32(8):504. PubMed ID: 38985364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxegol for managing opioid-induced constipation.
    Shelton KN; Clements JN
    JAAPA; 2017 Sep; 30(9):51-53. PubMed ID: 28858018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.